Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marika Vezzoli has a total of 264 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A curative-intent treatment program in older AML: mature posttransplant results from the VEN-DEC GITMO study

    by Daniele Avenoso, Mirko Farina, Alessandro Leoni, Nicola Polverelli, Simona Bernardi, Stella Santatore, Erika Borlenghi, Francesco Onida, Luca Castagna, Stefania Bramanti, et al.

  • Open Access

    Proximity extension assay-based serum proteomic profiling identifies shared protein signatures in hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders

    by Valeria Cinquina, Giulia Carini, Nicola Chiarelli, Marika Vezzoli, Valeria Bertini, Marina Venturini, Woodrow Gandy, Marina Colombi, Marco Ritelli

    Hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) are prevalent conditions characterized by symptomatic joint hypermobil


  • Open Access

    Preclinical evaluation of progesterone combined with EDP-M scheme in 2D and 3D models of adrenocortical carcinoma

    by Mariangela Tamburello, Andrea Abate, Caterina Boldini, Claudia Bonera, Gaia Faustini, Arianna Bellucci, Barbara Buffoli, Lorena Giugno, Deborah Cosentini, Marta Laganà, et al.


  • Open Access

    A visual mining analysis of middle meningeal embolization and other factors associated with recurrence requiring re-operation in subdural hematomas: a single-center series

    by Marco Battistelli, Marika Vezzoli, Iacopo Valente, Massimo Benenati, Giuseppe Garignano, Andrea Alexandre, Ludovico Agostini, Samuele Santi, Ottavia Giovinazzo, Leonardo Nardini, et al.

    Purpose: to comprehensively and hierarchically assess risk factors for recurrence requiring reoperation (RrR) in chronic subdural hematoma (cSDH) in the era of middle meningeal artery embolization (MMAE). Methods: Patients treated for a cSDH from January 2019 to October 2024 at Fondazione Gemelli research hospital were considered for inclusion. Clinical, coagulation, radiological, and treatment factors were recorded. MMAE was performed systematically from October 2022, using polyvinyl alcohol (PVA) particles injected directly from the main trunk of MMA. The dataset comprised 45 quantitative and qualitative variables for each cSDH. Variables showing statistical significance (p-value < 0.05) were selected as covariates in two supervised learning frameworks to predict the RrR (outcome, Y ): ( i ) Classification and Regression Tree (CART) and ( ii ) Random Forest (RF) classifier. Results: 500 patients were eligible and 233 were included, resulting in 283 treated cSDHs (mean follow-up: 119 days); 129 underwent adjuvant MMAE. 50 cSDH had a RrR (mean time to recurrence: 47 days), of which 41 (82%) in the non-embolized group and 9 (18%) in the embolized group (p-value < 0.001). Adjuvant embolization was the strongest factor associated with RrR, significantly reducing the risk for reintervention. Markwalder grading scale, preoperative cSDH volume, and platelet count (PLT) are strong predictors in non-embolized patients. A critical PLT cut-off of 229 × 10 9 /L strongly impacts RrR risk for substantial cSDH volumes. Conclusions: The present results support the routine use of MMAE and the correction of PLT in relation to cSDH volume.


  • Open Access

    Interplay Between Protein Phosphatase 2A (PP2A) and SE Translocation (SET) as Macromolecular Target of Anticancer Compounds: A Combined Computational and Experimental Study

    by Giovanni Ribaudo, Mario Angelo Pagano, Margrate Anyanwu, Matteo Giannangeli, Marika Vezzoli, Andrea Visentin, Federica Frezzato, Livio Trentin, Anna Maria Brunati, Alessandra Gianoncelli

    Cancer represents a leading cause of mortality globally, with its complex biological nature posing significant challenges for treatment. Central to cancer progression are molecular pathways that govern cellular function, among which protein phosphatase 2A (PP2A) plays a vital role. As a serine/threonine phosphatase, PP2A maintains cellular homeostasis by dephosphorylating a broad range of protein substrates and has emerged as a key tumor suppressor. However, PP2A activity can be physiologically inhibited by endogenous regulators such as the SE Translocation (SET) protein. Overexpression of SET has been associated with the loss of PP2A function, promoting hallmark features of cancer. Interestingly, targeting the PP2A/SET interaction has shown therapeutic potential. Indeed, inhibiting SET to reactivate PP2A may restore cellular regulation, induce apoptosis in tumor cells, and attenuate cancer progression. Research efforts have explored compounds such as the endogenous D-erythro-C18-ceramide and the drug fingolimod (FTY720), both known for their ability to reactivate PP2A. In this work, PP2A/SET complex models were generated through a computational approach and, using molecular docking, the interaction of potential SET inhibitors from a library of 26 alkoxy phenyl 1-propan-one derivatives (APPDs) was characterized. Additionally, absorption, distribution, metabolism, and excretion (ADME) predictions were performed to assess pharmacokinetic properties and therapeutic potential. Eventually, the predicted binding affinities were then correlated with biological data to assess the reliability of the models. These findings provide valuable insights into molecule–receptor interactions and lay the groundwork for developing inhibitors with encouraging therapeutic implications.


  • Open Access

    Developmental coordination disorder and cerebral visual impairment: What is the association?

    by Serena Micheletti, Marika Vezzoli, Jessica Galli, Paola Mattei, Andrea Rossi, Giulia Paderni, Lotfi B. Merabet, Elisa Fazzi

  • Open Access

    Radiomic and Clinical Model in the Prognostic Evaluation of Adenoid Cystic Carcinoma of the Head and Neck

    by Paolo Rondi, Michele Tomasoni, Bruno Cunha, Vittorio Rampinelli, Paolo Bossi, Andrea Guerini, Davide Lombardi, Andrea Borghesi, Stefano Maria Magrini, Michela Buglione, et al.

    Background/Objectives: Adenoid Cystic Carcinoma (AdCC) is a rare malignant salivary gland tumor, with high rates of recurrence and distant metastasis. This study aims to stratify patients Relapse-Free Survival (RFS) using a combined model of clinical and radiomic features from preoperative MRI. Methods: This retrospective study included patients with primary AdCC who underwent surgery and adjuvant radiotherapy. Segmentations were manually performed by two head and neck radiologists. Radiomic features were extracted using the 3D Slicer software. Descriptive statistics was performed. A Survival Random Forest model was employed to select which radiological feature predict RFS. Cox proportional hazards models were constructed using clinical, radiological variables or both. Synthetic data augmentation was applied to address the small sample size and improve model robustness. Models were validated on real data and compared using the C-index and Prediction Error Curves (PEC). Results: Three Cox models were developed: one with clinical features (C-index = 0.67), one with radiomic features (C-index = 0.68), and one combining both (C-index = 0.77). The combined clinical-radiomic model had the highest predictive accuracy and outperformed models based on clinical or radiomic features. The combined model also exhibited the lowest mean Brier score in PEC analysis, indicating better predictive performance. Conclusions: This study demonstrate that a combined radiomic-clinical model can predict RFS in AdCC patients. This model may provide clinicians a valuable tool in patient’s management and may aid in personalized treatment planning.


  • Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial

    by Domenico Russo, Nicola Polverelli, Simona Bernardi, Stella Santarone, Mirko Farina, Erika Borlenghi, Francesco Onida, Luca Castagna, Stefania Bramanti, Angelo Michele Carella, et al.


  • Open Access

    A Mediterranean Diet-Oriented Intervention Rescues Impaired Blood Cell Bioenergetics in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

    by Agnese Segala, Marika Vezzoli, Alice Vetturi, Emirena Garrafa, Barbara Zanini, Emanuela Bottani, Monica Marullo, Silvia Marconi, Chiara Ricci, Alessandra Valerio

    Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a novel term for Non-Alcoholic Fatty Liver Disease (NAFLD), is associated with liver mitochondrial dysfunction. We previously demonstrated that mitochondrial respiratory capacity in peripheral blood mononuclear cells (PBMCs) was significantly reduced in patients with MASLD compared to non-MASLD controls. For MASLD treatment, guidelines recommend behavioral and dietary changes to reduce body weight. A recent 12-month clinical trial demonstrated that ameliorating patients’ lifestyles through improved adherence to the Mediterranean diet and encouraged physical activity results in MASLD remission or regression. Methods: As a sub-study of the 12-month clinical trial, we evaluated the effects of the Mediterranean diet-oriented intervention on PBMC mitochondrial DNA content and respiratory parameters and on various biomarkers associated with MASLD. Results: Contrary to what was found at the baseline, after twelve months of intervention, systemic inflammatory and bioenergetics parameters did not differ between MASLD patients (N = 15) and control subjects (N = 17). PBMCs from MASLD subjects showed rescued basal respiration, ATP-linked respiration, maximal respiration, and spare respiratory capacity. The observed recovery coincided with a significant increase in the patients’ adherence to the Mediterranean diet (Medscore). Conclusions: Our findings indicate that a Mediterranean diet-oriented intervention, without calorie reduction, preserves blood cell mitochondrial function in MASLD subjects. Thus, PBMC bioenergetics-based assays might be taken into account not only for diagnosing but also for monitoring therapeutic responses in MASLD.


  • Open Access

    Effects of Limbs’ Spasticity on Spinopelvic Alignment in Post-Stroke Patients: A Cross-Sectional Study

    by Luciano Bissolotti, Alice Brojka, Marika Vezzoli, Stefano Calza, Federico Nicoli, Carlos Romero-Morales, Jorge Hugo Villafañe

    Objectives: This study aimed to determine the impacts of upper and lower limb (UL and LL) spasticity and impairment on spinal alignment in chronic post-stroke patients. Methods: A total of 45 consecutive chronic post-stroke patients, 18 women and 27 men, from 18 to 70 years old who presented post-stroke hemiparesis were recruited in this cross-sectional study. The clinical assessment included the Modified Ashworth Scale (UL-MAS and LL-MAS spasticity), Upper Limb Motricity Index (UL-MI), FAST-UL, and Five Times Sit-to-Stand Test (5T-STS); the Associated Reaction Rating Scale was used to measure associated reactions in the hemiparetic UL, the plumb line distance from the spinous process of C7 on the sagittal (PL-C7s) and frontal plane (Pl-C7f), the kyphosis apex (PL-AK), and the spinous process of L3 (PL-L3). Angular measures of spinal alignment were measured by a Bunnell scoliometer™ (angle of trunk rotation—ATR) and a gravity-dependent inclinometer (inclination at C7-T1 and T12-L1). Results: In chronic post-stroke patients, there was found to be an association between the 5T-STS and PL-C7f (β = 0.41, p = 0.05) and the angle of inclination at T12-L1 (β = 0.44, p = 0.01). The FAST-UL correlated with PL-C7f (β = −0.41, p = 0.05), while the UL-MI correlated with this last parameter (β = −0.36, p = 0.04) and the ATR (β = −0.31, p = 0.05). The UL-MAS showed correlation with the ATR (β = 0.38, p = 0.01). Conclusions: The results lead to the possibility that, in chronic post-stroke patients, spinal misalignment on the frontal and sagittal plane is associated both with strength impairment and UL spasticity. The improvement or restoration of spinopelvic parameters can take advantage of therapeutic interventions targeted at motor improvement and spasticity reduction of the hemiparetic side.